After a majority stake in its ownership was acquired by MOHS Analytics, Inc. in the last quarter of 2024, Remed Pharmaceuticals recorded accelerated sales in the first half of 2025. Sales in the first semester grew by 88 percent versus target, and 35 percent growth over the same period in 2024. Growth in the quarter ending June 2024 was even more impressive with 102 percent growth over target and 70 percent increase over the previous year.
Sales at the Mercury Drug chain increased at a remarkable rate, doubling over the same period last year.
Accounting for the growth in sales was the increase in the distribution footprint in major key accounts and national chain drugstores with outlets increasing from 2,500 to 4,000 nationwide, ensuring broader accessibility and visibility. Remed is focusing on establishing at least 80 percent presence for “Must Carry” brands in Mercury, Watsons, Generika, and other major chain drugstores nationwide. As a result of this focus, five new products with seven SKUs were included at these major drug stores.
“At Remed Pharma, we believe that growth is not just measured in numbers but in the trust we build with our partners, the innovation we bring to our products, and the lives we improve through accessible healthcare,” says MOHS CEO Michael B. Hortaleza. “With Artificial Intelligence quickly disrupting society, product innovation and digitalization will drive our growth and efficiency gains. As we advance towards our 2031 vision, we remain true to the vision of founder Remedios A. Rivera of a highly innovative and research-oriented company always ready with new products that respond to global and local health developments.”
Remed grew all of its four therapeutic categories—Mouth Antifungal, Respicare, Gastrocare and Vita lines—with a deliberate marketing push to ensure equitable share of voice in medical promotions.
A digital platform was also deployed by its medical representatives to drive prescription generation among doctors. Marketing efforts emphasize program execution that enhances awareness among target healthcare professionals supported by above-the-line marketing promotion for Over the Counter products.
“Even with Remed’s fast growth and aggressive investments, it has successfully maintained strong profitability and effective cost controls. We remain fully committed to our five-year roadmap, which aligns closely with the CEO’s strategic direction,” says MOHS SVP and Group CFO Dr. Kenji M. Asano, Jr. “Despite global economic headwinds, the healthcare sector continues to expand and will deliver steady year-on-year growth for MOHS group-wide.”
Remed was founded as a research and development oriented pharmaceutical company. To ensure a continuous flow of products through its development pipeline and expand its product mix, Remed initiated an 8-quarter product planning roadmap, which is expected to enable Remed to launch new pediatric line extensions and introduce innovative, first-to-market offerings in new therapeutic classes. MOHS Analytics acquired majority ownership of Remed Pharmaceuticals in pursuit of its strategy of vertical integration of its flagship healthcare and wellness business. The acquisition is in line with MOHS’s 5-year road map to grow into one of the Philippines’ largest fully integrated health and wellness companies.
